CJC-1295 with DAC (5mg)

Modified GHRH Analog with Drug Affinity Complex

The 4Balance Codex: Sustained-Release Growth Hormone Secretagogue Architecture.

Product Overview

CJC-1295 with DAC is a tetrasubstituted, 30-amino acid peptide hormone that functions as a long-acting analog of Growth Hormone Releasing Hormone (GHRH). Unlike standard Mod GRF 1-29, this research compound is engineered with Drug Affinity Complex (DAC) technology. This chemical modification allows the peptide to form a covalent bond with circulating serum albumin, protecting it from rapid enzymatic degradation and extending its active window from minutes to days.

Format: 5mg Lyophilized Powder Purity: >99% (HPLC Analysis) Sequence Modification: Lysine linker to N-epsilon-3-maleimidopropionyl-2-aminohexanoyl (DAC)

Mechanism of Action: Albumin Bioconjugation

The defining characteristic of this compound is its ability to hijack the body’s own transport mechanisms to prolong its effect.

1. Protective Binding: Upon introduction to the research subject, the reactive group on the DAC moiety binds specifically to the Cys34 residue of serum albumin.

2. Enzymatic Shielding: This bioconjugation shields the peptide from degradation by the enzyme Dipeptidyl Peptidase-IV (DPP-IV), which typically destroys unmodified GHRH in under 7 minutes.

3. Extended Pharmacokinetics: By "piggybacking" on albumin, CJC-1295 with DAC achieves an active half-life of approximately 6 to 8 days in clinical models. This results in a sustained, rather than pulsatile, elevation of basal Growth Hormone (GH) and Insulin-Like Growth Factor 1 (IGF-1) levels.

Research Applications

In the 4Balance Research Array, CJC-1295 with DAC is the primary agent for investigating long-term endocrine manipulation without the need for frequent administration.

• Sustained IGF-1 Elevation: Research indicates this compound can increase total plasma IGF-1 levels by 1.5 to 3 times for up to a week after a single administration.

• Lipolysis & Metabolism: Studies observe significant increases in fatty acid oxidation (fat loss) due to the persistent presence of GH, independent of dietary restriction.

• Somatotroph Hypertrophy: Used to study the density of GH-secreting cells in the anterior pituitary gland.

Comparison Note: Unlike Ipamorelin or CJC-1295 (No DAC) which mimic natural pulsatile spikes, the DAC variant creates a "bleed" effect of GH release, maintaining higher baseline levels continuously.

Technical Specifications

• Molecular Formula: C165H269N47O46

• Molecular Mass: 3647.28 g/mol

• Vial Quantity: 5mg

• Solubility: Water Soluble (Requires Bacteriostatic Water for reconstitution)

• Storage: Lyophilized peptides are stable at room temperature for up to 90 days but should be stored in a freezer below -8°C for extended periods. Once reconstituted, store at 4°C.

References

1. Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism.

2. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J. Clin. Endocrinol. Metab.

3. Sackmann-Sala, L., et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes. Growth Hormone & IGF Research.

4. Jetté, L., et al. (2005). Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats. Endocrinology.

5. Castiel, M. H., et al. (2006). Efficacy and safety of CJC-1295 in patients with HIV-associated visceral adiposity. Aids Research Study.

DISCLAIMER: FOR RESEARCH USE ONLY. This product is a laboratory reagent intended strictly for in-vitro research and development. It is not for human consumption, veterinary use, or therapeutic application. Bodily introduction of any kind is strictly prohibited by law.